Biotechnology company focusing on progressing psychedelic therapeutics by utilizing drug discovery and delivery for various psychiatric and neurological conditions Cybin Inc. (NEO: CYBN) (OTCMKTS: CLXPF) announced having received a conditional listing approval from the New York Stock Exchange American LLC.
Any listing is always subject to approval of the NYSE American and all applicable regulatory requirements must be satisfied before the company is listed. NYSE American maintains that no guarantee is given than an application will be approved.
The company says it plans to maintain its NEO Exchange listing and it has reserved the ticker ‘CYBN’ on the NYSE American.
“Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions,” said the company’s CEO, Doug Drysdale.